Minnesota Secures $35 Monthly Insulin Cap in Landmark Settlement with Novo Nordisk
The agreement concludes a multi-year legal battle, ensuring affordable insulin access for Minnesotans and setting a five-year price cap.
- Novo Nordisk is the third major insulin manufacturer to settle with Minnesota, agreeing to cap monthly insulin costs at $35 for five years.
- The settlement follows similar agreements with Eli Lilly and Sanofi as part of Minnesota’s lawsuit alleging price-fixing and deceptive practices.
- Minnesota Attorney General Keith Ellison emphasized the agreement's enforceability, contrasting it with voluntary price cuts that lack binding guarantees.
- The settlement also includes provisions for free insulin supplies to qualifying low-income residents, addressing broader affordability concerns.
- Minnesota's efforts reflect growing national pressure for pharmaceutical companies to ensure fair and transparent pricing for essential medications.
Star Tribune 
